Detail akcie Myriad Genetics online

Business Summary: Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Myriad Genetics, Inc. revenues increased 11% to $753.2M. Net loss increased from $112M to $263.3M. Revenues reflect United States segment increase of 14% to $671.7M. Higher net loss reflects Legal settlements increase from $0K to $112.8M (expense), SBC in Gen and Admin increase of 10% to $529.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.39 to -$3.18.